BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

For younger acute myocardial infarction (AMI) survivors, living in marginalized neighborhoods is associated with adverse ...

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

In recent months, Karnataka has witnessed a disturbing rise in sudden cardiac deaths among young individuals—many of them ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Treating coronary artery disease patients with monotherapy using clopidogrel or ticagrelor was associated with lower rates of ...

For younger acute myocardial infarction (AMI) survivors, living in marginalized neighborhoods is associated with adverse ...

Spiritual engagement — not religious affiliation — was linked to lower stress markers and improved outcomes in patients with ...